On this page
What it is
A single molecule that activates two incretin receptors — GIP and GLP-1 — rather than GLP-1 alone.
How it is proposed to work
Combined GIP and GLP-1 receptor agonism affecting insulin secretion, glucagon, gastric emptying and central appetite regulation. The precise contribution of the GIP component in humans is still debated.
Approved medical uses
Type 2 diabetes and chronic weight management, with jurisdiction-specific labelling.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Randomised controlled trial2022n = 2,539
Phase 3 placebo-controlled trial in obesity, diabetes excluded (SURMOUNT-1)
Finding. In adults with obesity, or with overweight plus a weight-related complication and diabetes excluded, 72 weeks of once-weekly tirzepatide met both coprimary endpoints: mean body weight fell by roughly 15% to 21% across the tirzepatide groups against about 3% with placebo, and the large majority of tirzepatide-treated participants lost at least 5% of body weight, compared with about a third on placebo. Gastrointestinal adverse events were the most common, mostly mild to moderate and concentrated in the escalation period.
Limitation. The comparison was against placebo only, so this trial says nothing about tirzepatide versus GLP-1 receptor agonists. Adults with diabetes were excluded, so it does not support the type 2 diabetes indication at all. Endpoints were weight and cardiometabolic measures over 72 weeks, not clinical outcomes, and the trial was funded by the manufacturer.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- CautionEstablished
Gastrointestinal adverse effects are common, dose-related, and a frequent cause of discontinuation.
Known interactions and contraindication considerations
- Delayed gastric emptying can affect oral drug absorption.
- Hypoglycaemia risk rises in combination with insulin or insulin secretagogues.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Approved as of 15 Jan 2026 |
Two distinct brand approvals for distinct indications. |
European Union EMA | Approved as of 15 Jan 2026 | Centrally authorised; check current indication wording. |
India CDSCO | Approved as of 15 Jan 2026 | Prescription-only. Confirm current CDSCO approval scope and available presentations. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
Weight management
What is run
Labelled titration, or a slower self-directed titration intended to reduce gastrointestinal effects by spending longer at each step.
Their mechanistic reasoning
That dual GIP and GLP-1 agonism produces greater effect than GLP-1 alone, and that slower titration improves tolerability without reducing the eventual result.
Reported in the community’s own terms. Not our position.
Stacked with
- Resistance training and a protein target—Same lean-mass logic as any incretin therapy.
Regimen shape
- Dose
- figure withheld
- Scale
- Labelled titration steps, sometimes extended
- Route
- Subcutaneous injection
- Frequency
- Weekly
- Timing
- Fixed day
- Duration
- Continuous
Our read
The slower-titration reasoning is sound and mirrors what clinicians often do anyway, since gastrointestinal effects are dose- and escalation-rate-related. The contribution of the GIP component in humans remains genuinely debated, so claims about why it works better than semaglutide are more confident than the evidence supports.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
Broadly regarded as more effective than semaglutide, and cross-trial comparison is repeated as settled fact when it is not. The slower self-titration practice is one of the more sensible things the community has arrived at on its own.
Commonly reported as helping
- Greater appetite suppression than reported with semaglutide by people who used both
- Better tolerability at comparable effect, according to some who switched
- Faster loss at equivalent effort
Also reported, when it goes wrong
- Gastrointestinal effects still the dominant complaint
- Sulphur-tasting burps, reported distinctively and often
- Fatigue during rapid loss
- Same regain pattern after stopping
Why these reports can mislead
Switch reports are the weakest common evidence type and the most cited here. Anyone switching has usually plateaued, changed dose, and renewed their effort simultaneously — attributing the result to the molecule alone ignores three other changes.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- Gastrointestinal effects are the main cause of discontinuation and track with escalation rate.
- Hypoglycaemia risk rises alongside insulin or sulfonylureas — a prescriber needs to adjust those.
Active clinical trials
- NCT00000002Phase 3Recruitingn = 1,400
Dual incretin agonism in type 2 diabetes with chronic kidney disease
Type 2 diabetes; chronic kidney disease · United States, Japan, India · updated 19 Jul 2026
What remains unknown
The questions that would change our assessment if they were answered.
- How much does the GIP component contribute independently in humans?
- What do long-term cardiovascular and renal outcomes look like relative to GLP-1 monotherapy?
References
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Scheduled review. No change to evidence grade.
Spotted something wrong? Tell us — we publish corrections.